Jun Dong

A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer

Tae Won Kim, Anneli Elme, Zvonko Kusić et al. · British Journal of Cancer · 2016 · 72 citations · Full text

Medicine, Cancer Biology, Gastrointestinal Oncology +14

PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck

Lori J. Wirth, Shaker R. Dakhil, Gabriela Kornek et al. · Oral Oncology · 2016 · 30 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Treatment of Huge Hepatocellular Carcinoma Using Cinobufacini Injection in Transarterial Chemoembolization: A Retrospective Study

Jun Dong, Xiaofeng Zhai, Zhe Chen et al. · Evidence-based Complementary and Alternative Medicine · 2016 · 25 citations · Full text

Medicine, Oncology, Pharmacology +9

Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study

Nitin Udar, Catherine Lofton–Day, Jun Dong et al. · Journal of Cancer Research and Clinical Oncology · 2018 · 25 citations · Full text

Medicine, Bioinformatics, Oncology +17

Expression of the vascular endothelial growth factor family in tumor dissemination and disease free survival in clear cell renal cell carcinoma

J. S. Lam, John T. Leppert, Hao Yu et al. · Journal of Clinical Oncology · 2005 · 23 citations

Medicine, Cancer Biology, Oncology +17